There has been a belief among some that taking aspirin would enhance the chances of survival from the novel coronavirus causing "COVID-19." However, a new study has disproved this notion. This belief particularly pertains to patients infected with the coronavirus who require hospitalization and may face blood issues. Researchers at the University of Oxford in the UK found that the inexpensive and widely available aspirin does not improve the survival rates of COVID-19 patients in hospitals.
The researchers had hoped to find evidence that aspirin could help coronavirus patients at risk of blood clots, but they discovered that aspirin does not aid in preventing deaths. The Oxford study was part of the broader "RECOVERY" trial, aimed at investigating various potential treatments for those infected with the coronavirus.
The study included 15,000 hospitalized COVID-19 patients, with about half receiving 150 milligrams of aspirin daily compared to the other half who received standard medical care. The study concluded that "there is no evidence that aspirin treatment reduces mortality," as there was no significant difference between the two groups, with around 17% of both groups dying in the hospital after 28 days of treatment.
